|
|
|
|
|
|
|
1448. Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with Crohn diseaseJurij Hanžel, Erwin Dressen, Séverine Vermeire, Mark Löwenberg, Frank Hoentjen, Peter Bossuyt, Esmé Clasquin, Filip J. Baert, Geert R. D'Haens, Ron Mathôt, 2022, original scientific article Keywords: therapeutic drug monitoring, exposure-response, pharmacometrics, inflammatory bowel disease, Crohn's disease, drug clearance, endoscopy, pharmacodynamics, infusion procedures, disease remission, vedolizumab, therapy Full text (file, 2,05 MB) This document has more files! More... |
1449. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel diseaseJurij Hanžel, Jeroen M. Jansen, Rinze W. F. ter Steege, Krisztina B. Gecse, Geert R. D'Haens, 2022, original scientific article Keywords: SB2, CT-P13, multiple switches, Crohn's disease, inflammatory bowel disease, ulcerative colitis, adults, feces, c-reactive protein, infliximab, adverse event, leukocyte l1 antigen complex, infusion procedures, biosimilar pharmaceuticals, disease remission, imputation, antidrug antibody, infliximab-dyyb Full text (file, 608,73 KB) This document has more files! More... |
|